Leland Ellis, PA
Medical · Winterville, NCNPI 1386749695
Payments from drug & device makers
Across 409 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$772
- AstraZeneca$540
- Pfizer$526
- Amgen$414
- Takeda Pharmaceuticals U.S.A., Inc.$345
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,429100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 91 | $1,272 |
| Novo Nordisk | 51 | $772 |
| AstraZeneca | 24 | $540 |
| Pfizer | 35 | $526 |
| Amgen | 30 | $414 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $345 |
| Boehringer Ingelheim | 22 | $338 |
| Lilly USA, LLC | 20 | $311 |
| Otsuka America Pharmaceutical, Inc. | 12 | $240 |
| Abbott | 8 | $171 |
| Idorsia Pharmaceuticals US Inc | 11 | $167 |
| Eisai Inc. | 8 | $127 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $121 |
| Amarin Pharma, Inc. | 8 | $117 |
| Merck | 8 | $113 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $86 |
| Esperion Therapeutics, Inc. | 5 | $86 |
| Corium, LLC | 4 | $82 |
| Kowa Pharmaceuticals America, Inc. | 6 | $74 |
| Axsome Therapeutics, Inc. | 4 | $73 |
| Phathom Pharmaceuticals, Inc. | 3 | $58 |
| Currax Pharmaceuticals LLC | 3 | $55 |
| Organogenesis Inc. | 1 | $49 |
| Ironshore Pharmaceuticals Inc. | 3 | $44 |
| Optinose US, Inc. | 2 | $42 |
| Scynexis, Inc. | 2 | $40 |
| Novartis | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Genentech USA, Inc. | 2 | $27 |
| Lundbeck LLC | 1 | $24 |
| Boston Scientific | 1 | $21 |
| Tris Pharma Inc | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Cipher Pharmaceuticals US LLC | 1 | $15 |
| GSK | 1 | $14 |
How this compares
$6,454 in reported general payments places this provider in the 90th percentile of 878 medical providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 68 | $69,804 |
| OzempicSemaglutide | 32 | $35,524 |
| JardianceEmpagliflozin | 33 | $31,104 |
| JanuviaSitagliptin Phosphate | 26 | $27,747 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $27,517 |
| FarxigaDapagliflozin Propanediol | 26 | $25,768 |
| RybelsusSemaglutide | 24 | $18,993 |
| TrulicityDulaglutide | 16 | $14,548 |
| MyrbetriqMirabegron | 23 | $13,211 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $7,558 |
| Spiriva HandihalerTiotropium Bromide | 12 | $6,184 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $5,618 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $4,783 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $3,971 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 122 | $3,954 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $526 | $69,80468 claims |
| Novo NordiskOzempic, Rybelsus | $772 | $54,51756 claims |
| AstraZenecaFarxiga, Symbicort | $540 | $33,32654 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $14 | $31,48951 claims |
| Boehringer IngelheimJardiance | $338 | $31,10433 claims |
| MerckJanuvia | $113 | $27,74726 claims |
| Lilly USA, LLCTrulicity | $311 | $14,54816 claims |
| AbbVieSynthroid | $1,272 | $2,70638 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 878 medical providers in North Carolina.
Other medical in Winterville
- Grace McLaurinHickory$553K
- Joel ThompsonCharlotte$269K
- Virginia JethroCary$213K
- Payal Soni-PatelAsheville$76K
- William JarrettElkin$59K
- Amanda ZimmermanWinston Salem$48K
- David TaylorMorehead City$40K
- Katherine CardSalisbury$39K
- John RobbinsWinston Salem$26K
- Ashley TipperStatesville$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.